{"protocolSection":{"identificationModule":{"nctId":"NCT02285387","orgStudyIdInfo":{"id":"4-2014-0728"},"organization":{"fullName":"Yonsei University","class":"OTHER"},"briefTitle":"Rhythm Control of AF in Patients With Acute Stroke"},"statusModule":{"statusVerifiedDate":"2019-03","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-11"},"primaryCompletionDateStruct":{"date":"2019-08","type":"ESTIMATED"},"completionDateStruct":{"date":"2019-08","type":"ESTIMATED"},"studyFirstSubmitDate":"2014-10-31","studyFirstSubmitQcDate":"2014-11-03","studyFirstPostDateStruct":{"date":"2014-11-07","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-03-25","lastUpdatePostDateStruct":{"date":"2019-03-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Yonsei University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Prospective randomized (rhythm control or rate control) Objective of study\n\n1. To analyze long term outcome of patients with acute stroke with atrial fibrillation according to the rhythm control\n2. To analyze recurrence rate of atrial fibrillation or recurrence stroke in patients with acute stroke according to the rhythm control (by antiarrhythmic drug, cardioversion, catheter ablation)"},"conditionsModule":{"conditions":["Atrial Fibrillation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":300,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Rhythm control group","type":"EXPERIMENTAL","description":"1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation\n2. Cardioversion after 1 month\n3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)\n4. If AF recur, RFCA","interventionNames":["Procedure: Rhythm control"]},{"label":"Rate control group","type":"ACTIVE_COMPARATOR","description":"1. No AAD, just anticoagulation\n2. HR control between 60\\~110bpm (with beta blocker, calcium channel blocker, digoxin)\n3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study.","interventionNames":["Procedure: Rate control"]}],"interventions":[{"type":"PROCEDURE","name":"Rhythm control","description":"1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation\n2. Cardioversion after 1 month\n3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)\n4. If AF recur, RFCA","armGroupLabels":["Rhythm control group"]},{"type":"PROCEDURE","name":"Rate control","description":"1. No AAD, just anticoagulation\n2. HR control between 60\\~110bpm (with beta blocker, calcium channel blocker, digoxin)\n3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study.","armGroupLabels":["Rate control group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"acute stroke with AF","description":"Long term outcome of rhythm control in patients with acute stroke with AF related to all cause morality, hospital admission, recurrence rate of stroke, major adverse cardiac events","timeFrame":"1 year"},{"measure":"recurrence of silence stroke","description":"Adverse events after anticoagulation or anti arrhythmic drug, recurrence rate after RFCA on AF in patients with stroke, adverse events after RFCA, recurrence rate of silence stroke or clinical stroke","timeFrame":"1 year"},{"measure":"recurrence of AF after rhythm control","description":"Adverse events after anticoagulation or anti arrhythmic drug, recurrence rate after RFCA on AF in patients with stroke, adverse events after RFCA, recurrence rate of silence stroke or clinical stroke","timeFrame":"1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients with Atrial fibrillation (20\\~80 years old)\n2. patients with Acute stroke within 7 days\n3. LA diameter \\< 55mm\n4. patients possible to anticoagulation and anti arrhythmic drug\n5. NIHSS score â‰¤12\n\nExclusion Criteria:\n\n1. Hemorrhagic transformation\n2. Large cerebral lesion or cerebellar lesion (more than 1/3 of MCA area and 1/2 of ACA area, 1/2 of PCA area, 1/2 of cerebellar area)\n3. active internal bleeding\n4. Impossible to anticoagulation or anti arrhythmic drug\n5. Valvular AF (MA\\> GII, Mechanical valve, Mitral valve replacement)\n6. LV ejection fraction \\< 30%\n7. Structural cardiac disease\n8. Catheter ablation history for AF, Cardiac surgery\n9. Already prescribed anti arrhythmic drugs\n10. With severe medical disease\n11. Expected survival \\< 1year\n12. Severe alcoholics, drug addiction\n\n14. Contraindication to MRI 15. Pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Hui-Na Pak, MD","role":"CONTACT","phone":"82-2-2228-8459"}],"locations":[{"facility":"Severance Cardiovascular Hospital, Yonsei University Health System","status":"RECRUITING","city":"Seoul","zip":"120-752","country":"Korea, Republic of","contacts":[{"name":"Hui-Nam Pak, M.D., Ph.D.","role":"CONTACT","phone":"82-2-2228-8459","email":"hnpak@yuhs.ac"}],"geoPoint":{"lat":37.566,"lon":126.9784}}]},"referencesModule":{"references":[{"pmid":"35043663","type":"DERIVED","citation":"Park J, Shim J, Lee JM, Park JK, Heo J, Chang Y, Song TJ, Kim DH, Lee HA, Yu HT, Kim TH, Uhm JS, Kim YD, Nam HS, Joung B, Lee MH, Heo JH, Pak HN; RAFAS Investigators*. Risks and Benefits of Early Rhythm Control in Patients With Acute Strokes and Atrial Fibrillation: A Multicenter, Prospective, Randomized Study (the RAFAS Trial). J Am Heart Assoc. 2022 Feb;11(3):e023391. doi: 10.1161/JAHA.121.023391. Epub 2022 Jan 19."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M5071","name":"Calcium","relevance":"LOW"},{"id":"M5088","name":"Calcium, Dietary","relevance":"LOW"},{"id":"M6955","name":"Digoxin","relevance":"LOW"},{"id":"M3361","name":"Adrenergic beta-Antagonists","relevance":"LOW"},{"id":"M3903","name":"Anti-Arrhythmia Agents","relevance":"LOW"},{"id":"M5074","name":"Calcium Channel Blockers","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"BDCA","name":"Bone Density Conservation Agents"},{"abbrev":"AnArAg","name":"Anti-Arrhythmia Agents"},{"abbrev":"CaAg","name":"Cardiotonic Agents"},{"abbrev":"ChanBlk","name":"Channel Blockers"}]}},"hasResults":false}